# HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

> **NCT00349349** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 223 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic

## Interventions

- **DRUG:** ofatumumab

## Key facts

- **NCT ID:** NCT00349349
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-05
- **Final completion:** 2012-06
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2014-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349349, "HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00349349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*